Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,144.00
(
0.54%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.66
(
2.40%
)
Bitcoin
74,524.89
(
-0.43%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: zipjet post# 110658

Friday, 12/10/2010 3:39:31 PM

Friday, December 10, 2010 3:39:31 PM

Post# of 257253

If memory serves me, this is the THIRD CP filed by TEVA on Copaxone and the first two were rejected not only as premature but with reasons rejecting many of the arguments TEVA advanced.

That’s right. Teva’s first Copaxone CP was rejected by the FDA because it was filed prematurely and Teva’s second CP (the one referenced in my previous post) was rejected by the FDA on the merits.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now